跳至主要内容
临床试验/CTRI/2018/09/015790
CTRI/2018/09/015790已完成未知

A prospective randomized double blind placebo controlled study evaluating the efficacy of inj midazolam 0.05 mg/kg for prevention of emergence agitation in children aged 1 - 6 years undergoing general anaesthesia with inhaled sevoflurane.

Hinduja National Hospital0 个研究点目标入组 64 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ASA 1 and 2 patients Scheduled for elective surgery of more than 1 hour duration.

排除标准

  • ASA 3 and above. Below 1 year and more than 6 years of age
  • Emergency surgery
  • Active Respiratory cardiac disease, neurological disease with delayed mental development

研究者

发起方
Hinduja National Hospital

相似试验

招募中
1 期
Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trialnovel coronavirus pneumonia (NCP)
ITMCTR2000002964Zhejiang Chinese Medical University
已完成
4 期
Does infiltration of local anaesthesia improve recovery after anterior hip replacement?total hip replacementlocal infiltration analgesiapostoperative recoveryAnaesthesiology - Pain managementMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disorders
ACTRN12615000844549Dr Nicole Tan160
进行中(未招募)
不适用
A clinical trial to study the effects of dipyridamole eye drops in the patients with symptomatic ocular surface conjunctival degenerative lesions i.e. pinguecula and pterygium.
CTRI/2018/08/015480OD Ocular Discovery Ltd
已完成
4 期
A clinical trial to study the effect of atorvastatin on pancreatic beta-cell function & insulin resistence in patients with type 2 diabetes mellitus
CTRI/2008/091/000099Department of Pharmacology AIIMS New Delhi42
进行中(未招募)
1 期
Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after standard treatment with bacterial lysates Paspat 3 mg tablets, over an observation period of six months.upper respiratory tract infections in children at high risk of reccurence.
EUCTR2016-000979-24-ITDaiichi Sankyo Italia SpA210